Medical Oncologist
Targeted Therapy
CDK4/6 Inhibitors in — Hormone-Positive Breast Cancer
CDK4/6 inhibitors — palbociclib, ribociclib and abemaciclib — are targeted oral drugs used in hormone receptor-positive, HER2-negative breast cancer. They slow tumour growth by blocking the enzymes that cancer cells depend on to divide.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Three approved drugs — Palbociclib, ribociclib and abemaciclib are all included in NCCN and ESMO guidelines for eligible patients.
- Always with hormone therapy — CDK4/6 inhibitors are combined with an aromatase inhibitor or fulvestrant — not used alone.
- Oral, taken at home — All three are tablets or capsules. No hospital admission is needed for these drugs themselves.
- Early and metastatic settings — Depending on your stage and risk profile, they may be offered in early or advanced breast cancer.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
CDK4/6 inhibitors — palbociclib, ribociclib and abemaciclib — are targeted oral drugs used in hormone receptor-positive, HER2-negative breast cancer. NCCN and ESMO guidelines recommend them in combination with hormone therapy for eligible patients. They block enzymes called CDK4 and CDK6 that cancer cells depend on to divide.
How do CDK4/6 inhibitors work in breast cancer?
Hormone receptor-positive breast cancer cells use oestrogen signals to grow. They also depend on two enzymes — CDK4 and CDK6 — to drive cell division. CDK4/6 inhibitors block both enzymes, putting that division on pause.
Hormone therapy alone slows the oestrogen signal. Adding a CDK4/6 inhibitor targets a separate part of the growth process. NCCN and ESMO guidelines include this combination as a standard approach for eligible HR-positive, HER2-negative disease.
The drugs are taken by mouth at home. No hospital admission is needed for the CDK4/6 inhibitor itself.
Which of the three CDK4/6 inhibitors might you be prescribed?
Palbociclib is taken once daily in cycles, with a rest period between each cycle. It is the most established of the three in years of global use.
Ribociclib follows a similar on-off cycle pattern. Your team will do periodic ECG checks because ribociclib can affect the heart's electrical activity. This is a monitoring precaution, not a reason to avoid the drug for most people.
Abemaciclib is taken twice daily without a scheduled rest period between cycles. It tends to cause more diarrhoea than the other two but holds approval for both metastatic disease and certain high-risk early-stage breast cancer.
Your oncologist will choose based on your menopausal status, the hormone therapy you are paired with, any other health conditions, and what is available locally.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What side effects should you watch for?
Neutropenia — a fall in white blood cells — is the most common concern with palbociclib and ribociclib. Blood tests before each new cycle let your team catch this early. A low count does not automatically mean a dose reduction.
Fatigue is common across all three drugs. Most people find it manageable after the first few weeks.
Diarrhoea is more frequent with abemaciclib. Your team will usually prescribe anti-diarrhoeal medicine alongside it. Persistent or severe diarrhoea is a reason to call the same day, not to wait for a scheduled appointment.
Mouth sores, nausea and mild hair thinning occur in a proportion of patients. Liver enzyme changes are detected through routine blood tests and are usually asymptomatic.
What else should you know about CDK4/6 inhibitors?
How do I know if I am eligible?
Eligibility rests on three things: your tumour is hormone receptor-positive and HER2-negative on pathology testing, your stage and risk profile fit the indication, and your general fitness allows treatment. You do not need a separate genetic test — the receptor status from your biopsy is what determines it. If your receptor status has not been clearly explained, ask for the pathology report at your next visit and ask your oncologist what it means for your treatment options.
How long will I take this medicine?
In metastatic disease, CDK4/6 inhibitors are continued for as long as the cancer is responding and you are tolerating them — this can extend across months to years. In high-risk early-stage disease, NCCN and ESMO guidelines support a defined course rather than indefinite use. Your oncologist will outline the planned duration at your first treatment review. It is reasonable to ask at that appointment what the stopping criteria are and what will prompt a reassessment.
I am premenopausal. Can I still have this treatment?
Yes. CDK4/6 inhibitors are used in premenopausal women, combined with ovarian suppression and an aromatase inhibitor or tamoxifen. ESMO and NCCN guidelines include premenopausal women in the eligible population. If you have not yet started a family, discuss fertility preservation before beginning any of these treatments — ovarian suppression during treatment is not a substitute for egg or embryo freezing, and that conversation needs to happen early.
Will this treatment affect my ability to have children?
CDK4/6 inhibitors must not be taken during pregnancy and require effective contraception throughout. Whether they affect longer-term fertility is an area where data are still maturing. ASCO recommends discussing egg or embryo freezing before starting if you may want children later. Oestrogen-containing contraceptives are not suitable alongside hormone-positive breast cancer treatment, so ask your team what contraception is appropriate for you while on these drugs.
What happens if the CDK4/6 inhibitor stops working?
Most cancers eventually develop resistance to CDK4/6 inhibitors. When this happens, your oncologist will reassess — usually with imaging and sometimes a new biopsy — to look for changes in tumour biology that guide the next step. Several options exist after CDK4/6 inhibitor failure, including other targeted therapies, clinical trials and chemotherapy. Being on one of these drugs now does not close any of those doors; the decision about what comes next is made based on how the disease is behaving at that point.
Are CDK4/6 inhibitors available in India?
All three drugs — palbociclib, ribociclib and abemaciclib — are available in India on oncologist prescription. Cost is a real consideration; these are among the more expensive oral cancer medicines. Manufacturer patient assistance programmes exist for some of them, and your oncologist or the CION team can advise on what support may be accessible for your situation. Never start, stop or switch between these medicines without telling your treating oncologist — the choice between them is not interchangeable.
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
What type of breast cancer is treated with CDK4/6 inhibitors?
CDK4/6 inhibitors are used in hormone receptor-positive, HER2-negative breast cancer — often written HR+/HER2−. They are not used in HER2-positive or triple-negative breast cancer. Your pathology report confirms your receptor status. If you are unsure what the result means for your treatment, ask your oncologist to go through it with you before any treatment decision is made.
Can a CDK4/6 inhibitor be taken with food?
Palbociclib should be taken with food, which improves how well it is absorbed. Ribociclib and abemaciclib can be taken with or without food, though taking them at the same time each day helps keep blood levels consistent. Your pharmacist will give you written instructions when you collect the prescription. If you have been taking it inconsistently with meals, mention it at your next cycle review rather than making an abrupt change yourself.
What should I do if I miss a dose?
Do not double up to compensate. If you miss a dose and it is still the same day, take it as soon as you remember. If the next day has started, skip the missed dose and continue your usual schedule. Read the patient leaflet that came with your specific drug — each one has slightly different instructions. If you miss several doses in a row for any reason, tell your oncologist before your next cycle so the blood results can be read in that context.
Will I lose my hair on CDK4/6 inhibitors?
Some hair thinning is reported, but it is generally mild and does not cause the complete loss associated with chemotherapy. If you are also receiving chemotherapy at any stage of your treatment, hair loss from that is a separate effect and follows a different pattern. Mention any noticeable change to your team — they can confirm whether the medicine is likely to be the cause and whether any adjustment is warranted.
What does neutropenia mean and when do I need to call?
Neutropenia means your white blood cell count — the cells that fight infection — is lower than normal. It is common with palbociclib and ribociclib and is monitored through blood tests before each cycle. A low count may cause a short cycle delay, a dose adjustment, or no change at all, depending on how low it is and whether you have symptoms. Call your team the same day if you develop any fever during treatment — fever alongside a low white cell count needs prompt assessment, not a wait-and-see approach.
Is CDK4/6 inhibitor treatment available at CION?
Yes. CDK4/6 inhibitors are oral medicines taken at home, and CION oncologists can prescribe and oversee the full treatment course alongside regular clinic visits for cycle reviews, blood monitoring and side effect management. Response-assessment scans, including PET-CT when your oncologist indicates it, are coordinated with partner imaging centres. Contact your nearest CION centre if you have been told you may need this treatment and would like to discuss your options.